News
02-15-2009, 02:01 PM
A newly published study in The New England Journal of Medicine shows that in premenopausal women with early breast cancer administering Zometa(R) (zoledronic acid) along with post-surgery hormone therapy provided a reduction in risk of recurrence or death that was 36% beyond that achieved with hormone therapy alone(1).
More... (http://www.news-medical.net/?id=45865)
More... (http://www.news-medical.net/?id=45865)